Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Purinergic dysregulation causes hypertensive glaucoma–like optic neuropathy
Youichi Shinozaki, Kenji Kashiwagi, Kazuhiko Namekata, Akiko Takeda, Nobuhiko Ohno, Bernard Robaye, Takayuki Harada, Takeshi Iwata, Schuichi Koizumi
Youichi Shinozaki, Kenji Kashiwagi, Kazuhiko Namekata, Akiko Takeda, Nobuhiko Ohno, Bernard Robaye, Takayuki Harada, Takeshi Iwata, Schuichi Koizumi
View: Text | PDF
Research Article Neuroscience Ophthalmology

Purinergic dysregulation causes hypertensive glaucoma–like optic neuropathy

  • Text
  • PDF
Abstract

Glaucoma is an optic neuropathy characterized by progressive degeneration of retinal ganglion cells (RGCs) and visual loss. Although one of the highest risk factors for glaucoma is elevated intraocular pressure (IOP) and reduction in IOP is the only proven treatment, the mechanism of IOP regulation is poorly understood. We report that the P2Y6 receptor is critical for lowering IOP and that ablation of the P2Y6 gene in mice (P2Y6KO) results in hypertensive glaucoma–like optic neuropathy. Topically applied uridine diphosphate, an endogenous selective agonist for the P2Y6 receptor, decreases IOP. The P2Y6 receptor was expressed in nonpigmented epithelial cells of the ciliary body and controlled aqueous humor dynamics. P2Y6KO mice exhibited sustained elevation of IOP, age-dependent damage to the optic nerve, thinning of ganglion cell plus inner plexiform layers, and a reduction of RGC numbers. These changes in P2Y6KO mice were attenuated by an IOP lowering agent. Consistent with RGC damage, visual functions were impaired in middle-aged P2Y6KO mice. We also found that expression and function of P2Y6 receptors in WT mice were significantly reduced by aging, another important risk factor for glaucoma. In summary, our data show that dysfunctional purinergic signaling causes IOP dysregulation, resulting in glaucomatous optic neuropathy.

Authors

Youichi Shinozaki, Kenji Kashiwagi, Kazuhiko Namekata, Akiko Takeda, Nobuhiko Ohno, Bernard Robaye, Takayuki Harada, Takeshi Iwata, Schuichi Koizumi

×

Figure 5

Reduction of IOP prevents RGC damage.

Options: View larger image (or click on image) Download as PowerPoint
Reduction of IOP prevents RGC damage.
(A) Daily topical administration o...
(A) Daily topical administration of latanoprost to P2Y6KO mice over 4 months reduced the basal IOP to that of WT mice (n = 10–20, *P < 0.05 vs. WT 6 months, ##P < 0.01 vs. P2Y6KO 6 months, 1-way ANOVA followed by Fisher’s LSD test). (B) Thinning of ganglion cell layer and inner plexiform layer (GCL/IPL) in 6-month-old P2Y6KO mice observed by OCT was restored by daily latanoprost administration (n = 10–20, *P < 0.05, **P < 0.01 vs. WT 6 months, ##P < 0.01 vs. P2Y6KO 6 months, 1-way ANOVA followed by Fisher’s LSD test). (C and D) Latanoprost prevented the reduction in RGC number in 6-month-old P2Y6KO mice (n = 25, **P < 0.01 vs. WT 6 months, ##P < 0.01 vs. P2Y6KO 6 months, 1-way ANOVA followed by Fisher’s LSD test). Values are the mean ± SEM. Scale bars: 100 μm in B and C, 250 μm in B.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts